Radiation Induced Metabolic Alterations Associate with Tumor Aggressiveness and Poor Outcome in Glioblastoma

Authors: Kshama Gupta[1], Ivan Vuckovic[2], Song Zhang[2], Yuning Xiong[1], Brett L. Carlson[3], Joshua Jacobs[1], Ian Olson[1], Xuan-Mai Petterson[2], Slobodan I. Macura[2], Jann Sarkaria[3], Terry C. Burns[1]

Affiliation:
[1]Department of Neurologic Surgery, Mayo Clinic, Rochester MN, USA
[2]Metabolomics core Mayo Clinic, Rochester MN, USA.
[3]Department of Radiation Oncology, Mayo Clinic, Rochester MN, USA

Corresponding Authors:
Terry C. Burns, M.D., Ph.D.,
Department of Neurological Surgery, Mayo Clinic
200 1st St SW
Rochester, MN 55905
Email: burns.terry@mayo.edu

Kshama Gupta, Ph.D.
Department of Neurological Surgery, Mayo Clinic
200 1st St SW
Rochester, MN 55905
Email: gupta.kshama@mayo.edu

Running Title: RT-induced metabolic changes in the tumor microenvironment worsen GBM outcome.

Keywords: Radiation therapy (RT), Glioblastoma (GBM), Recurrence, Tumor microenvironment (TME), Metabolomics.

Figures: 5, Supplementary figures: 3, Supplementary Table: 1, Supplementary Excel sheets: 3, Supplementary methods 1

Word Count: 5883

Abstract

Glioblastoma (GBM) is uniformly fatal with a one year median survival rate, despite the best available treatment, including radiotherapy (RT). Impacts of prior RT on tumor recurrence are poorly understood but may increase tumor aggressiveness. Metabolic changes have been investigated in radiation-induced brain injury; however, the tumor-promoting effect following prior radiation is lacking. Since RT is vital to GBM management, we quantified the tumor-promoting effects of prior radiotherapy (RT) on patient-derived intracranial GBM xenografts and characterized the metabolic alterations associated with the protumorigenic microenvironment. Human xenografts (GBM143) were implanted into nude mice 24h following 20Gy cranial radiation vs. sham animals. Tumors in pre-radiated mice were more proliferative and more infiltrative, yielding faster mortality (p<0.0001). Histologic evaluation of tumor associated macrophage/microglia (TAMs) revealed cells with a more fully activated ameboid morphology in pre-radiated animals. Microdialyzates from the radiated brain at the margin of tumor infiltration contralateral to the site of implantation were analyzed by unsupervised liquid chromatography-mass spectrometry (LC-MS). In pre-radiated animals, metabolites known to be associated with tumor progression (like, modified nucleotides and polyols) were identified. Whole-tissue metabolomic analysis of the pre-radiated brain microenvironment for metabolic alterations in a separate cohort of nude mice using ^{1}H-NMR revealed significant decrease in levels of antioxidants (glutathione (GSH) and ascorbate (ASC)), NAD+, TCA intermediates, and increased ATP and GTP. Glutathione and ASC showed highest VIPpred (1.65) in OPLS-DA analysis. Involvement of ASC catabolism was further confirmed by GC-MS. To assess longevity of radiation effects, we compared survival with implantation occuring 2 months vs. 24h following radiation, finding worse survival in animals implanted at 2 months. These radiation-induced alterations are consistent with a chronic disease-like microenvironment characterized by reduced levels of antioxidants and NAD+, as well as elevated extracellular ATP and GTP serving as chemoattractants, promoting cell motility and vesicular secretion with decreased levels of GSH and ASC exacerbating oxidative stress. Taken together, these data suggest that IR induces tumor-permissive changes in the microenvironment with metabolomic alterations that may facilitate tumor aggressiveness with important implications for recurrent glioblastoma. Harnessing these metabolomic insights may provide opportunities to attenuate RT-associated aggressiveness of recurrent GBM.

1. Introduction

Glioblastoma multiforme (GBM; WHO grade IV) is the most common adult primary brain malignancy (1,2), accounting for 50% of all gliomas across all age groups (2). Standard treatment includes surgical resection, radiation therapy (RT), and chemotherapy; however, the overall five-year survival rate is <10% with mortality approaching 100% (3,4) is unfavorable prognosis may be due to the high propensity of tumor recurrence, with many recurring within one year, and 90% of these tumors forming within the prior RT field (5-7).

Radiation-induced changes in the brain and tumor microenvironment injury resulting in molecular, cellular, and functional changes that can facilitate tumor aggressiveness upon recurrence(8). Such changes include decreased vascularity, innate immune activation, and altered pharmacokinetics, pharmacodynamics, and therapeutic efficacy of chemotherapy agents (9-12). Additionally, irradiation (IR) generated reactive oxygen and nitrogen species (ROS/NOS) play havoc with cellular proteins, DNA and phospholipid membrane (13). Mitochondria exposed to radiation produce increased reactive oxygen species (ROS), that may contribute to RT-induced cell senescence (14-16).

Tumor cell metabolism is strikingly different from that of normal cells with a shift from energy-producing pathways to those generating macromolecules necessary for proliferation and tumor growth. Through a tricarboxylic acid cycle (TCA), healthy cells metabolize glucose and produce carbon dioxide within an oxygen-rich environment, which efficiently produces a large quantity of adenosine triphosphate (ATP) (17). In hypoxic environments, these cells produce large quantities of lactic acid by anaerobic glycolysis. Conversely, in aerobic conditions, tumor cells rely on glycolysis for energy production (18), resulting in elevated rates of glucose uptake and increase lactate production (19). Lactate production during active tumor growth alters the tumor microenvironment (TME) by promoting acidosis, serving as a metabolic cancer cell fuel source, and inducing immunosuppression. RT may also have immunosuppressive effects leading to increased tumor aggressiveness, with associated increases in proliferation and infiltration (20), which may be exacerbated by prior RT.

Metabolic alterations may be pro-tumorigenic, promoting glioma initiation and progression (21-24). RT-induced metabolic changes in GBM depend on tumor volume, location, and dose-time regime of RT-administration, all of which can vary treatment response (8,25-29). While differential metabolism of glioma tumor cells can be targeted to regress tumor growth, understanding the impact of radiation-induced metabolic alterations in GBM microenvironment can provide new avenues to maximize long term benefits of RT in GBM care. The major objective of this study is to investigate the interactions between irradiation, tumor aggressiveness, and the associated metabolic changes in the tumor microenvironment. We quantify the tumor-promoting effects of prior radiotherapy (RT) on patient-derived intracranial GBM xenografts in mice and characterize the metabolic alterations associated with the protumorigenic microenvironment.

2. Materials and Methods

2.1. Ethics statement on mice.

Six to eight weeks old female heterozygous Hsd: Athymic Nude -Foxn1nu/Foxn1+ mice were purchased from Envigo (Indianapolis, IN). Six to eight-week-old male C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, ME). Mice were housed at the Mayo Clinic animal care facility, which is Association for Assessment and Accreditation of Laboratory and Animal Care International (AAALACI)-accredited. Aging was induced in two separate cohorts of C57BL/6J mice [fed with regular diet or high-fat diet (D12492, Research diets)] by keeping them in-housed for 24 months at the Mayo Clinic animal care facility, i.e. a small cohort of 5 mice (2 months old) was maintained for 22months fed throughout on regular diet to obtain an aged mice group (24month old), and, another cohort of 5mice (2 months old) was fed on high-fat-diet (HFD) to induce obesity and continued on HFD for 22 months to obtain an aged-obese mice group (24month old). All animal procedures were performed with proper animal handling, adhering to the National Institutes of Health (NIH) guidelines and protocols approved by the Institutional Animal Care and Use Committee (IACUC) at Mayo Clinic, Rochester.

2.2. Cranial irradiation of mice

Cranial irradiation was administered using the X-RAD SmART irradiator (Precision X-ray, North Branford, CT), which uses a cone beam CT (CBCT) for accurate target localization. The stereotactic coordinates were determined from the target-set on CBCT using the first scan for each mouse within all groups (values ranged between x = 0.25 to 0.35, y = -3.8 to -4.0, and z = -5.8 to -5.95, depending on mice and strain-type). Whole brain radiotherapy was performed as described (30), using parallel opposed lateral beams with 10mm square collimator. Radiation treatments included 10, 15, or 20Gy single dose [20Gy] administration, or 4Gyx10 dose-fractionation. Control group mice were handled similarly as the treated, but with no radiation dose administered (0Gy).

2.3. Intracranial injections in mice

Intracranial injections in athymic nude mice were performed as previously described (31). Briefly, GBM143 cells were obtained from flank tumors and cultured *in vitro*. These cultured cells were dissociated using TryplE (Cat# 12563011, Thermo Scientific) and resuspended in PBS at a concentration of 100,000 cells/μl (with injection volume 3μl/mouse). Mice were anesthetized using Ketamine: Xylazine mixture (100mg/kg Ketamine and 10mg/kg Xylazine) injected intraperitoneally (IP) with a 0.5cc syringe. The surgical procedure involved the following steps: disinfecting mice head with Betadine, lubricating the eyes with artificial tears, making a 1cm midline incision extending from just behind the eyes to the level of the ears using sterile scalpel while applying pressure to have the incision open. Using a cotton swab, the skull was cleared to have the bregma exposed, a point 1mm anterior and 2mm lateral from bregma was identified and drilled through the skull using an 8bit Dremel drill. For stereotactic injection, Hamilton syringe with a 26G needle assembly was cleaned thoroughly, fixed on the injection jig, and 3μl of cell suspension drawn into it. Injection jig was sterilized by wiping with STERIS Spor-Klenz and draping it with a sterile towel. The mouse having its skull drilled was placed on the jig and fixed using front teeth hook at mouthpiece and ear pins. Using the stereotactic controls, the needle was inserted 3mm deep into the brain and, 300,000cells/3μL were injected at a rate of 1μL/min for over 3min using the syringe pump. The needle was maintained as inserted in place inside the skull for additional 1min, and then drawn out gently using the stereotactic

controls. Mouse skull hole using sealed using bone cement, and the wound sutured with 4-0 vicryl with rb-1 needle (Ethicon J304H). Triple antibiotic was applied to the incision and stitches to prevent infection, and the mouse was left in the warm cage to recover from anesthesia. Water was supplemented with children's ibuprofen starting 24hrs prior to starting the procedure and continued for 48hrs post-surgery.

2.4. Histology and immunofluorescence

Athymic nude mice injected with the established PDX line, GBM143, were euthanized using isoflurane overdose at day of moribund (i.e. after 58days of tumor cell-implantation). PBS cardiac perfusion was performed prior to termination under fully anesthetized conditions to remove the circulating peripheral leukocytes from the brain. Brains were extracted, fixed in 10% buffered formalin for 24hours, paraffin embedded, and 5μm coronal sections were obtained. All processing after fixation was performed at Mayo Clinic Histology core, Scottsdale. For histologic analysis, slides were stained with hematoxylin and eosin (H&E) and visualized by bright field microscopy at 4X microscopic magnification using Leica DMI-6000B (software: Leica Application Suite X (Leica Microsystems, Wetzlar, Germany)). Percent positive HE stained area was assessed to estimate relative tumor burden between the samples.

HE stained sections were reviewed to identify appropriate tumor bearing regions and respective unstained slides processed for immunofluorescence staining with human Lamin A+C and Ki67 antibodies using standard procedure. Briefly, slides were deparaffinized in xylene and rehydrated by washing (3mins each) in serially diluted ethanol from 100%, 95%, 75%, 50%, and then distilled H_2O. Antigen retrieval was performed using pre-warmed 9.8mM Sodium citrate buffer (pH=6.0, with 0.05% Tween 20) for 30mins in hot steamer. Slides were rinsed in distilled H_2O and PBS, blocked in blocking solution (10% N goat serum and 1% BSA in PBS), and stained with primary antibody (diluted in blocking solution, 1:300) for overnight in humidified chamber at 4°C. The slides were washed in PBS (3x5mins), stained with secondary antibody (diluted in blocking solution, 1:300) for 2hrs at room temperature, washed, and mounted with ProLong Gold reagent having DAPI (P36935, Life Technologies). Images were acquired at 4X microscopic magnification and tiling done using Leica DMI-6000B (software: Leica Application Suite X).

2.4.1. Image analysis

All IF stained slides were quantified and scored for single cell count in a defined region with x-y coordinates approximated at tumor center (for Lamin A+C, and Ki67) or at centre of corpus callosum (for Lamin A+C), respectively, using Image J (32,33) and CellProfiler 2.2.0 (Broad Institute of Harvard and MIT) (34). Briefly, for single cell counting, an IF image obtained was imported into Image J, threshold was set, channels split, and image in relevant single channel was selected and converted to black and white (BW). An area template having fixed size was generated to define a contained region at tumor or at the center of corpus callosum, respectively, maintaining consistency between different sample slides. This defined area selectively masked was overlaid and appropriately positioned in the BW image, and all background cells out of the masked region were eliminated. The resultant image was transferred to CellProfiler 2.2.0 software (Broad Institute of Harvard and MIT) (34), the masked region was cropped and used as

input; the pipeline for single cell counting was run to detect nuclei and quantify cells within this defined region.

To evaluate microglial activation, slides were stained for Iba-1 using standard procedure for IF. Images represented with 20X magnification were acquired on Leica DMI-6000B (software: Leica Application Suite X) and 40X magnification on Zeiss Axio Observer Z.1 (Software: Zen 2.3 SP1, Jena, Germany). Microglial morphology was assessed using ImageJ (32,33). Antibodies used: Rabbit monoclonal Anti- h-Lamin A+C [EPR4100] (Cat# Ab108595, Abcam, Cambridge, United Kingdom); Rat monoclonal Ki67 (SolA15) (Cat #14-5698-82, eBioscience Invitrogen, Waltham, MA); Rabbit monoclonal Anti-Iba-1 (Cat# 019-19741, Wako). Secondary antibodies from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA) included polyclonal affinity-pure whole IgG:Cy3-Goat Anti-Rabbit IgG (H+L) (code: 111-165-003) and Cy5-Goat Anti-Rat IgG (H+L) (code: 112-175-143).

2.5. Microdialysis

To evaluate changes in the extracellular milieu of radiated brain, a small group of mice (3 mice per group) from 0Gy and 20Gy single-dose irradiated mice cohorts injected with GBM143 24hr post-IR, were microdialyzed on their contralateral hemisphere (non-tumor bearing side) at day 30 from tumor cell injection. The microdialysis set-up and surgical procedure was followed as described from the facility of Dr. Doo-Sup Choi, at Mayo Clinic (35). Briefly, the mice were housed singly for 2hrs in the microdialysis room to acclimatize, and then anesthetized using Ketamine:Xylazine mixture. Survival surgery was performed on a rotating platform with stereotactic guidance under sterile conditions. A microdialysis probe with a 2.0mm cellulose membrane (Brain Microdialysis, CX-I Series, Eicom, Kyoto, Japan; MW cut off: 50,000 Da) was inserted at a point 1mm anterior and 2mm lateral from bregma on the contralateral hemisphere and secured to the guide cannula. The probe was connected to a microsyringe pump (Eicom, Kyoto, Japan), which delivered Ringer's solution (145 mM NaCl, 2.7 mM KCl, 1.2 mM $CaCl_2$, 1.0 mM $MgCl_2$, pH 7.4) at a 1.0 µl/min flow rate. The samples were collected in 0.2ml collection tubes maintained at 4°C for 3.5 hrs, and then immediately frozen and stored at −80°C until analyzed.

2.6. Metabolomics

2.6.1. Proton Nuclear Magnetic Resonance spectroscopy (^{1}H-NMR)

Athymic nude mice, 0Gy-control, and 20Gy single-dose irradiated (10 mice per group) were sacrificed and immediately frozen in liquid nitrogen. Brian tissues were collected on dry ice and pulverized in liquid nitrogen. The pulverized mouse brain tissue (~55-60 mg) was homogenized and extracted with 300µl of ice-cold 0.6M perchloric acid ($HClO_4$) solution. Sample tubes were (36)extraction procedure was repeated on the pellets (with ~150µL $HClO_4$) and supernatant obtained from two rounds of extraction were combined and neutralized with 140µl of 2M potassium bicarbonate, $KHCO_3$. In 400µL aliquot of neutralized extract, 100µL of 0.1M phosphate buffer and 50µL of 1mM TSP-d4 in D_2O were added. Samples were vortexed for 20 seconds and transferred to 5mm NMR tubes. The NMR signal was acquired on Bruker AVANCE III 600 MHz instrument (Bruker, Billerica, USA). ^{1}H-NMR spectra were recorded

using 1D NOESY pulse sequence with presaturation (noesygppr1d) under the following conditions: 90-degree pulse for excitation, acquisition time 3.90s, and relaxation delay 5s. All spectra were acquired with 256 scans at room temperature (298K) with 64k data points and 8417Hz (14 ppm) spectral width. The recorded ^{1}H-NMR spectra were phase and baseline corrected using TopSpin 3.5 software (Bruker, Billerica, MA). The spectra were then processed using Chenomx NMR Suite 8.3 software (Chenomx Inc., Edmonton, Canada). The compounds were identified by comparing spectra to database Chenomx 600MHz Version 10 (Chenomx Inc., Edmonton, Canada) and literature data (36-42). Quantification was based on an internal standard (TSP-d4) peak integral. The metabolite concentrations were exported as µM in NMR sample and recalculated as µmol/g of wet tissue.

2.6.2. Gas chromatography–mass spectrometry (GC-MS)

For GC-MS analysis, 70µl neutralized brain extracts (approx. 6.4mg of tissue wet weight) from athymic nudes were obtained using perchloric acid extraction method with 2M $KHCO_3$ based neutralization as described for 1H-NMR, centrifuged at 10,000g for 10mins, and cleared supernatant collected in fresh 1.5ml eppendorf tubes. These samples were completely dried in a SpeedVac concentrator run overnight. They were subsequently methoximated using 10µL MOXTM reagent (Cat# TS-45950, ThermoScientific, Waltham, MA) at 30°C for 90min and then derivatized using 40µL of N-methyl-N-trimethylsilyl trifluoroacetamide with 1% trimethylchlorosilane (MSTFA+1% TMCS: Cat# TS48915, ThermoScientific, Waltham, MA) at 37°C for 30min. Metabolite levels were determined using GC-MS (Hewlett-Packard, HP 5980B) with DB5-MS column. GC-MS spectra were deconvoluted using AMDIS software (NIST, Gaithersburg, MD) and SpectConnect software (Georgia Tech, Atlanta, GA, USA) was used to create metabolite peaks matrix. The Agilent Fiehn GC/MS Metabolomics RTL Library (Agilent, Santa Clara, CA) was used for metabolite identification. Ion count peak area was used for analysis of the relative abundance of the metabolites (43).

Similar to above, whole brain extracts using perchloric acid method were also prepared from a cohort of C57BL/6J mice and evaluated by ^{1}H-NMR and GC-MS. C57BL/6J mice included in the study were divided into 5 groups (with 4-5 mice per group) as follows: control (0Gy), 20Gy single-dose irradiated, 4Gyx10 fractionation-dose irradiated, and, two aged (24mo) non-irradiated mice groups, aged (24mo): fed on regular diet and, aged-obese (24mo): induced with obesity using high-fat-diet. All mice otherwise were 5-6 months old.

2.6.3. Data analysis

Multivariate analysis of NMR data was performed using SIMCA 15 software (Sartorius Stedim Biotech, Göttingen, Germany). Principal component analysis (PCA) was used to detect any innate trends and potential outliers within the data. Supervised Partial Least Squares discriminant analysis (PLS-DA) and Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) were performed to obtain additional information including differences in the metabolite composition of groups, variable importance in the projection (VIP) values, and regression coefficients. OPLS-DA models were calculated with unit variance scaling and the results were visualized in the form of score plots to show the group clusters. The VIP values and regression coefficients were calculated to identify the most important molecular variables for the

clustering of specific groups. Nonparametric Wilcoxon rank sum test and Student T-test were performed to determine the statistically significant differences between the groups with significance considered at level ≤0.05.

2.7. Survival curves

Athymic nudes, grouped as control (non-irradiated, 0Gy) and irradiated with 20Gy single dose, were divided into two study cohorts: 1) Short-term IR: where 5 mice from each group were injected with GBM143 cells after short-term prior IR-exposure of 24hrs and 2) Long-term IR: where 5 mice from each group were maintained for 2months post-irradiation and then injected with GBM143 cells. Survival time (in days) for each mouse was recorded until 70days post tumor cell injection. The overall survival was calculated by Kaplan-Meier method and log-rank test was used to compare the survival curves (44). A p-value of ≤0.05 was considered to be statistically significant.

2.8. Statistical representation

The difference between specific metabolites or a parameter measured across two groups was estimated for p-value, q-value or False discovery rate (FDR), and Fold change (FC), as appropriate. Graphs were plotted using software(s): GraphPad Prism 8.2.0 (GraphPad, San Diego, CA), Heatmapper (Wishart Research Group, University of Alberta and Genome Canada) (45) and Microsoft Office Excel. Statistical significance is represented as p-values: *p≤0.05; **p≤0.01; ***p≤0.001, ****p≤0.0001, or, q-values, where specified.

3. Results

3.1 Effect of radiation on tumor growth, proliferation and migration:

The experimental strategy is shown in Figure 1 and Supplementary Figure 2. Mice were cranially irradiated with either 20Gy (single dose) or 0Gy (control). At 24hrs post-irradiation, a pre-established GBM line (GBM143) was injected into the mice brain. Tissues were collected at moribund and evaluated with histology for tumor growth. A small cohort of mice radiated with 10Gy (single dose) and injected with GBM143 line was also compared with the 0Gy and 20Gy cohorts for relative tumor burden using haematoxylin and eosin (H&E) staining. No difference in tumor size was observed between 0Gy and 10Gy; however, 20Gy irradiated samples had significantly higher percent of section area positive for tumor by H&E, indicating an overall faster rate of tumor growth (Supplementary Figure 1). Thus, 10Gy cohort was not pursued for further evaluation. Sections from 20Gy and 0Gy were analyzed for tumor growth and proliferation using human-Lamin A+C and Ki67 staining. Significantly larger tumors were observed in the 20Gy group. More h-Lamin A+C cells were seen in the corpus callosum of 20Gy mice (Figure 1B). Quantitative analysis was performed by counting both h-Lamin A+C and Ki67 within the tumor to evaluate proliferation. Similarly, h-Lamin A+C was assessed in the midline corpus callosum to evaluate cell migration towards the contralateral hemisphere, as illustrated in Figure 1C. Significantly higher numbers of h-Lamin A+C and Ki67 cells were seen in 20Gy mice, as compared to 0Gy control at tumor. Similarly, significantly higher h-Lamin A+C staining was observed in 20Gy compared to 0Gy mice in the midline corpus callosum, suggesting a higher number of cells migrating toward the contralateral hemisphere (Figure 1D).

3.2 Metabolomics

3.2.1 Microdialysis

To assess for radiation-induced changes in the extracellular milieu, a pilot experiment with intracranial microdialysis was performed (using a microdialysis probe with 2.0mm cellulose membrane for Brain Microdialysis, CX-I Series, Eicom; MW cut-off: 50KDa) as described (35), in the contralateral hemisphere of a small cohort of mice from each study group (0Gy and 20Gy) at day 30 post-irradiation and GBM143 injection. Microdialysates were analyzed for untargeted liquid metabolic profiling using liquid chromatography-mass spectrometry (LC-MS), as described (46) (Methods described in Supplementary Materials). Principal component analysis could separate the groups 0Gy and 20Gy, indicating metabolic changes in effect of irradiation. A trend toward elevated levels of metabolites relevant to cancer progression was observed in the 20Gy mice, including modified nucleotides (N6-methyladenosine, pseudouridine), polyol (myo-inositol, quebrachitol) detected in the 20Gy (Supplementary *Excel* Sheet 3). However, there were very limited identifiable metabolites with a total of <60 due to low sample volume obtained after a 3.5hr microdialysis run at run rate of 1ul/min (Supplementary *Excel* Sheet 3). Moreover, due to technical challenges involved with keeping ≥4 mice per group in microdialysis and the limited volume of microdialysates collected for evaluation, significant conclusions could not be made. We therefore utilized a whole tissue metabolomics approach in non-tumor bearing mice to evaluate the metabolic changes post-irradiation.

3.2.2 Proton nuclear magnetic resonance (^{1}H NMR) spectroscopic analysis

We sought to identify the radiation induced metabolic alterations in the brain stroma associated with the observed outcome of higher tumor growth and proliferation in 20Gy mice. The scheme for the mice groups involved is illustrated in Supplementary Figure 2A (i). Whole brain metabolomics was performed in two separate mouse strains, athymic nude mice and C57BL/6 mice. Athymic nude mice were included since the tumor study described above was performed with human-PDX line in athymic nudes; C57BL/6 mice were included to eliminate strain dependence and to avoid potential confounding effects of immunodeficient mice. An aged-C57BL/6 mice (24 months old) with and without diet-induced-obesity were analyzed to assess whether or not the radiation-induced metabolic changes in the brain were similar to those induced by aging or obesity-induced senescence. A small group of C57BL/6 mice were administered a fractionated dose of 4Gyx10 for comparative analysis.

Data from proton nuclear magnetic resonance (^{1}H NMR) spectroscopic analysis revealed clear separation of 0Gy and 20Gy mice cohorts from athymic nude mice, using PCA (Figure 2A(i)). Supervised Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) further separated the two groups based on metabolite composition differences with predicted-variable importance in the projection (VIP) values shown. The most important molecular variables for clustering of specific groups include glutathione (GSH) and ascorbate (ASC) having VIPpred 1.65, along with differences in ATP and GTP levels as potentially distinguishing characteristics. After IR a significant reduction of GSH, ASC, and NAD$^+$ levels were observed, along with increases in ATP and GTP. Additionally, an overall reduced trend in TCA intermediates was observed in 20Gy. The multivariate analysis of NMR data performed using SIMCA 15 software for C57BL/6 mice demonstrated separation of groups: Aged 24mo, Aged-Obese 24mo, Control (0Gy), 20Gy single-dose cranially irradiated, and 4Gyx10 cranial IR-

fractionated (Supplementary Figure 2A (ii)). Supervised Partial Least Squares Discriminant Analysis (PLS-DA) showed separation of all five groups. Specifically, the aged-groups (aged:24mo and aged-obese:24mo) were separated into a different component compared to the 0Gy, 20Gy, and 4Gyx10 groups (Figure 2B and Supplementary Figure 2A (ii)). There was a better separation of groups shown in model:M4 (aged, 0Gy and 20Gy) as compared to those shown in model:M5 (0Gy, 20Gy and 4Gyx10) (supplementary Figure 2 A(ii), Table 1 for model parameters). Comparing all irradiated mice (IR group: 20Gy and 4Gyx10 analyzed together) with 0Gy using PLS-DA and OPLS-DA showed significant group separation. The VIP-total and VIPpred value estimation indicated the metabolites most relevant to this group separation, which included GTP, ATP, GSH, and ASC (Supplementary Figure 2B).

The relative abundance of metabolites identified post-IR for 20Gy single dose from ^{1}H NMR for C57BL/6 mice showed reduction in GSH and ASC levels and an increase in ATP and GTP (Figure 2B). No significant difference was observed between 20Gy and 4Gyx10. Alterations specific to the aged-group involved increased levels of scyllo-inositol and sn-glycero-3-phosphocholine with concomitant reduction in O-phosphocholine. Other metabolites reduced significantly in aged-mice, were NAA (N-acetyl aspartate), neurotransmitters, and intermediates of TCA cycle. List of metabolites detected for athymic nude mice and C57BL/6 by ^{1}H NMR are included in Supplementary *Excel* sheet 1.

3.2.3 Gas chromatography–mass spectrometry (GC-MS)

Lysates prepared by perchloric acid extraction for ^{1}H NMR were further evaluated using Gas Chromatography–Mass Spectrometry (GC-MS). The heatmap for relative abundance of metabolites (i.e. changes in normalized total peak area for the metabolites) between athymic nude mice groups, 0Gy and 20Gy, cranial IR with single dose is illustrated in Figure 3A (i). While there was internal variation observed within these groups, only a few significantly altered metabolites in 20Gy were identified., which included an increased trend in urea and, a reduction in levels of creatinine (Crn), NAA (N-acetyl aspartate), and NAA/Crn ratio post-irradiation. Importantly, ascorbic acid was significantly reduced in 20Gy and threonic acid was increased, reflecting ascorbic acid catabolism. The heatmap for relative abundance of metabolites (i.e. changes in normalized total peak area for the metabolites averaged for all mice within each group) between the single dose cranially irradiated C57BL6 mice groups (Aged: 24mo, Aged-Obese: 24mo, Control (0Gy), and 20Gy) and fractionally irradiated 4Gyx10 is included in Figure 3B (ii). The clustering was performed using Heatmapper software, which clearly distinguished between aged mice and aged-obese mice from 20Gy and 4Gyx10 groups. The significantly altered metabolites between control (0Gy) and irradiated groups (20Gy and 40Gy-F) involved increased levels in urea but no significant change in Crn, N-acetyl aspartate (NAA), and NAA/Crn ratio. However, there was a consistent trend with reduced levels of ascorbic acid and increased levels of threonic acid observed post-irradiation. Collectively, the results of ^{1}H-NMR and GC-MS, indicate involvement of ROS clearance with active utilization of GSH and ASC as antioxidants. Scheme for ASC and GSH cycle in clearance of reactive oxygen species (ROS) and the role of GSH in regeneration of ASC is illustrated, along with intermediates of ascorbic acid catabolism are represented in Figure 3C. Expected metabolic alterations upon irradiation involve an increase in levels of ROS, utilization and reduction in GSH and ASC, with concomitant increase in by-products of ASC catabolism, threonic acid (ThrO), and Oxalic acid (OxA) as indicated (Figure 3C).

Other metabolites contributing to the separation of the groups in C57BL6 mice are shown in Supplementary Figure 3. There was no significant difference in levels of cholesterol in the aged-Obese group, which could be due to high internal variation observed within the groups or small cohort size of 5mice/group. However, there was a reduced trend in free fatty acids and overall higher cholesterol in group B, as compared to others. Notable metabolites separating the aged groups (aged-24m, and aged-Ob) from irradiated groups (20Gy and 4Gyx10) involved reduction in fumaric and succinic acids, and reduced levels of metabolic intermediates of glycolysis and Tricarboxylic Acid Cycle (TCA). Metabolic variations common to both aged and radiated mice cohorts included a rise in threonic acid, oxalic acid, D-allose, and myo-inositol. Additionally, there was a slightly higher trend in urea and Crn; however, this was not significant for either aged or irradiated mice groups. List of metabolites detected by GC-MS are included in Supplementary *Excel* sheet 2.

3.3 Immunostaining for microglia with Iba-1

To evaluate the inflammation caused by tissue irradiation and its crosstalk with injected GBM143 tumor cells, immunostaining was performed for microglia, with Iba-1 (Figure 4). Microglial morphology was assessed at 20X in ipsilateral (IH) and contralateral (CH) hemispheres for coronal slices from mice cerebral hemispheres, mice cranially irradiated with 0Gy and 20Gy-single dose, and injected 24hrs post-irradiation with GBM143 PDX line (Figure 4A, 4B). Microglia were observed to be enlarged, bushy, and branched for 0Gy-GBM143, as opposed to amoeboid for 20Gy-GBM143, indicating stages of higher activation and higher phagocytic activity for the 20Gy-GBM143 injected mice. To evaluate whether the observed microglial activation was a result of radiation alone or due to a combined effect of radiation with tumor injection, the microglial staining in ipsilateral hemispheres of 0Gy-GBM143 and 20Gy-GBM143 was compared with that of ipsilateral hemispheres of two separate mice cranially irradiated with 20Gy-single dose and not injected with any human-GBM PDX line. Intriguingly, negligible Iba1$^+$ microglia staining was observed in the brain slices of 20Gy-IR alone, indicating the observed microglial activation to be an effect of crosstalk between irradiation and tumor pathogenesis. Figure 4D illustrates their relevance in our experimental setting with maximum microglial activation and phagocytic activity observed in 20Gy mice.

3.4 Effect of radiation on GBM outcome

To further assess the effects of radiation-associated metabolic alteration on GBM outcome, survival analysis was performed in irradiated mice cohorts and their respective controls when injected with GBM143. To assess the short-term (ST-IR) or Long-term (LT-IR) effects of irradiation on GBM-outcome, the GBM143 cells were injected at two different time points: 1) 24hrs post-irradiation (ST-IR) or 2) two months post-irradiation (LT-IR). Significant reduction was seen in the survival of mice after irradiation ST-IR or, LT-IR (Figure 5). The combined graph of ST-IR and LT-IR further showed a significant difference is survival of 20Gy (ST-IR) and 20Gy (LT-IR), with median survival of 58 days and 51 days, respectively.

Collectively, our data demonstrate radiation-induced metabolic alterations, including a rise in energy carriers (ATP and GTP) and reduction in antioxidants (GSH and ASC) associated with tumor promoting cell processes (cell proliferation, migration and inflammation) and poor GBM outcome. The proposed model is illustrated in Figure 5B.

4. Discussion

This study aimed to identify the impact of high-dose radiation-induced brain injury on glioblastoma growth and aggressivity, and to probe the metabolic alterations in response to irradiation-associated growth. Radiation can severely impact the tumor microenvironment by altering the extracellular milieu at molecular and structural levels (8,25,47). Radiation treatment leads to production of ROS. Tumors adapt to oxidative stress through several mechanisms, including metabolic shifts and elevated antioxidant peptide production and intratumoral hypoxia generation (48-50). Metabolomics has emerged as the state-of-the-art approach to identify cancer cell state and biomarkers. Furthermore, metabolic profiling of tumor microenvironment can provide information on tumor cell fate (51-57). We evaluated the metabolic changes in the pre-irradiated brain microenvironment in response to 20Gy-IR and the association with observed tumor aggressivity and inflammatory microglial phenotype. Cell proliferation and migration are a direct function of the cell's energy state (21); therefore, we involved ^{1}HNMR to identify and quantify energy carriers as also described (21). Our data demonstrate elevated levels of ATP and GTP post 20Gy-IR, with reduced levels of antioxidants (glutathione and ascorbate) [Figure2]. This observation was conserved between both mice strains (athymic nudes and C57BL6) included in the study. Increased ROS levels are expected to occur in response to irradiation treatment, which can activate pro-tumorigenic signaling (21,22). Ascorbate and GSH serve as the prime cellular antioxidants. Glutathione can recycle itself and reduced ascorbate (58,59). A decline in relative abundance of ASC and concomitant rise in threonic acid was observed using GC-MS, which confirmed active ASC catabolism [Figure 3]. Decreased levels of ASC and GSH indicate active ROS scavenging. Their depletion due to increased demand can cause further accumulation of intracellular ROS.

ROS production is associated with DNA damage and cell death. However, chronically high levels of ROS in the tumor microenvironment can be pro-tumorigenic (50,60). Similarly, while ATP and GTP are essential components of cellular homeostasis, a rise in intracellular nucleotides (ATP and GTP) can cause their export out of the cell through extracellular vesicles, thus elevating extracellular levels of nucleoside and nucleotides (eATP, eGTP, adenosine and guanine) (61,62). Extracellular purinergic nucleotides can affect both stroma cell and tumor cell processes. Extracellular ATP has been implicated in facilitating chemotaxis of microglia, microglial activation, inflammation, and several neurological or neuropathological processes (63). Additionally, it can be internalized by tumor cells, increasing their intracellular ATP levels conferring metabolic reprogramming, increased tumor aggressivity, and treatment resistance (64-68). A recent lung cancer study has shown eATP to be involved in epithelial-to-mesenchymal transition, cell migration, and metastasis (69). While the biological functions of extracellular guanosine or eGTP are less studied than adenosine or eATP, their relative concentrations can co-vary, and biological functions of these nucleotides can cross-interact (70,71). GTP is an essential biomolecule that modulates cell signaling via G-proteins and small GTP-binding proteins to facilitate cell proliferation, cell migration, and vesicle trafficking, and, can modulate metabolism and tumor development (72-79). Exocytosis and vesicle secretion can further facilitate release of purinergic nucleotides, inflammatory molecules, enzymes, and ROS into the extracellular milieu, which collectively can alter the TME to become pro-tumorigenic (60,68,80-82) [Figure 5B].

The dose and time-dependence of radiation exposure can significantly alter the impact of RT on tumor microenvironment by affecting tumor or stromal cell behavior, migration, and treatment response (26,28,29,83-90). High-dose irradiation effects include hemorrhage, cognitive decline, neurodegeneration, and premature senescence, which can progress over time (91,92). To identify whether the 20Gy single dose led to aging-like metabolic phenotype or severe neurotoxicity, two aged-mice groups were included (aged (24mo) and aged-obese (24mo)) and their metabolic profiles were compared with 20Gy-IR in C57BL/6 mice cohorts. A hypofractionated treatment cohort 4Gyx10 (total dose=40Gy) was also included to evaluate its correlation with the 20Gy-single dose. Multivariate analysis of ^{1}HNMR data revealed a clear distinction between aged-mice groups from 20Gy-single dose [Figure2, Supplementary Figure 2].

The metabolic changes observed in aged and irradiated-mice differed markedly; however, a rise in myo-inositol was observed in both groups. Conversely, age-related markers, scyllo-inositol and sn-glycero-phosphocholine, were only increased in the aged-group, which was accompanied by an overall distinct metabolic signature of these groups in GC-MS [Figure 3, Supplementary Figure 3] (93-95). There were no significant differences in metabolic signatures between 20Gy single dose and 4Gyx10 (total 40Gy) fractionation, indicating the severity of 20Gy single dose-induced damage was nearly equivalent or slightly greater than the more clinically relevant 4Gyx10 fractionated treatment. Increased levels of urea and decreases in NAA and creatine (Cr) or Crn levels are observed in neuropathologies (86,96). We observed a slight increase in urea with radiation in both mouse strains, but NAA and creatinine levels were not consistent and demonstrated a decline only observe in athymic nude mice. These observations indicated a partial neurotoxic state induced by 20Gy-IR; however, it was not as severe as would be expected with higher-dose radiation, and no severe aging-like signatures were observed. This could in part be due to the time-dependence of the experiment, where mice brain samples were harvested for metabolic analysis 24hr after 20Gy-single dose administration, since the tumor injections were performed 24hrs post-IR.

The association between these metabolic effects and time since radiation was investigated by performing a survival study in two mice cohorts, including 1) mice were GBM143-injected 24hrs post-IR to assess immediate or short-term effects (ST-IR) of IR-induced alterations in stroma on tumor development and 2) mice were GBM143-injected 2months post-IR to assess long-term effects (LT-IR) of IR induced stromal alterations on tumor development. Shortest median survival was seen in the LT-IR cohort indicating progressive IR-induced damage in tumor stroma, making it more permissive for tumor growth and recurrence. This corresponds to progressive radiation-induced brain injury and increased susceptibility to progressive neuropathologies in patients treated with RT (97).

5. Conclusions

We identified an aggressive tumor behavior and microglial activation following 20Gy single dose brain radiation, which could become more severe with time. Moreover, we found metabolic alterations with a rise in energy carriers (ATP and GTP) and a decline in antioxidants ASC and GSH to associate with the observed tumor phenotype. Since glioblastoma inevitably reoccurs, these observations carry important implications for the impact of the previously radiated microenvironment on the relative aggressiveness of recurrent glioblastoma. Sustained and progressive alterations in the RT-exposed brain microenvironment could worsen GBM outcome.

6. Future direction

The role of antioxidants in compromising the therapeutic effect of RT and pro-oxidants in sensitization to RT has long been debated (98-109). Radiation therapy mediates its effects directly or indirectly by production of ROS, thereby causing oxidative damage to macromolecules and induction of apoptosis. Therefore, increased expression of antioxidant peptides in tumors have been thought to reduce the cytotoxic effects of radiotherapy, and GSH inhibition is proposed to have therapeutic advantage in sensitizing cells to RT (59,110). Ascorbate can act as a pro-oxidant in acidic microenvironments, such as tumors (111); thus, it may function as a radio-sensitizer for glioblastoma cells and a radioprotector for normal cells post-RT (112,113). While discrepancies remain regarding ASC's role as a radio-sensitizer or radio-protector in glioblastoma, its potential as an anticancer agent has been reviewed (114-117).

Our study demonstrates an immediate effect of prior exposure to high-dose irradiation in the non-tumor/untransformed brain cells as decrease in antioxidant levels, including GSH and ASC consistent with their utilization to neutralize RT-induced free radicals. The depletion of these antioxidants can lead to further acute or chronic oxidative stress, altering the brain tumor microenvironment, which may contribute to the enhanced aggressiveness of recurrent tumors. While radiation-induced oxidative stress is necessary for DNA damage in tumor cells, this study raises the question if GSH and ASC administration after completion of radiation could help mitigate the radiation-induced metabolic stress in the microenvironment. If the post-radiation redox state contributes to tumor aggressiveness, there may be an opportunity to attenuate the RT-associated aggressiveness of recurrent GBM, enhancing the long-term safety of brain radiation treatment for glioblastoma.

Author contributions
KG and TB led the project, contributed to experimental design, review, and discussion. TB supervised and supported KG. KG, YX, and BC carried-out mice tumor experiments, KG conducted survival studies. BC supervised KG on irradiator operation. KG performed immunostainings. IO assisted KG. KG, JJ collaborated to analyze images. KG, IV, and SZ performed ^{1}H NMR and GC-MS studies, and data analysis. Metabolomics core provided support with LC-MS and data analysis. All authors contributed to experiments and research execution. Figures provided by KG and IV. Illustrations created by KG. All authors contributed to manuscript writing, research, editing and final review.

Conflicts of interest
The authors have no conflicts of interest to declare.

Disclosures

The authors have no financial conflicts of interest to declare.

Contribution to the field

Radiation therapy (RT) is used as a mainstay treatment modality for cancers, and >50% of all cancer patients receive RT at some stage of their treatment course. RT is the standard of care for glioblastoma has been shown to prolong survival; however, GBM survivors exhibit RT-induced side effects with progressive neuropathological symptoms. Moreover, tumors invariably recur in >90% of all GBM patients. Recent studies have shown damaging side effects caused by RT-exposure of normal tissues surrounding tumors that can cause changes in the brain parenchyma, which can facilitate an aggressive tumor recurrence. Significant advances in radiation therapy have been made to minimize these side-effects, such as image-guided focal radiation treatments or low-fractionated dose administration of total radiation dose (usually of <6Gy/dose fractions) for tumor eradication; however, high-dose radiation treatments are sometimes inevitable during surgical or treatment procedures. Additionally, studies show that late-delayed-effects of low-dose RT treatments can be mimicked by immediate effects of high-dose RT treatments; thus, patients progress to have the same damage as high-dose treatment but in a slow progressive manner over time. Therefore, it is necessary to find alternative post-radiation therapy approaches, which can alleviate tissue intrinsic changes that continue to otherwise progress after RT, leading to late pathological symptoms permitting tumor recurrence. Our work shows that an immediate effect of high-dose IR administration is an increase in energy metabolism in the tissue with decline in levels of tissue antioxidants. Such changes, if left unattended, can fuel the dormant tumor cells that are left after the primary treatment and propagate tumor activation. Thus, administration of antioxidants, such as Glutathione or ascorbate (Vitamin-C) as a post-therapeutic approach can have potential implications in lessening the propensity of tumor recurrence after RT ;thereby, also permitting possibilities for use of higher-radiation doses in tumors that are otherwise inaccessible or uncurable by low-fractionated treatment doses.

References

1. Wen, P.Y., and Kesari, S. Malignant gliomas in adults. N Engl J Med (2008) 359:5, 492-507. doi: 10.1056/NEJMra0708126

2. Louis, D.N., Perry, A., Reifenberger, G., Von Deimling, A., Figarella-Branger, D., Cavenee, W.K., et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (2016) 131:6, 803-820. doi: 10.1007/s00401-016-1545-1

3. Deen, D.F., Chiarodo, A., Grimm, E.A., Fike, J.R., Israel, M.A., Kun, L.E., et al. Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy. Organ System Program, National Cancer Institute. J Neurooncol (1993) 16:3, 243-272. doi: 10.1007/bf01057041

4. Kleihues, P., and Sobin, L.H. World Health Organization classification of tumors. Cancer (2000) 88:12, 2887. doi: 10.1002/1097-0142(20000615)88:12<2887::aid-cncr32>3.0.co;2-f

5. Stupp, R., Hegi, M.E., Gilbert, M.R., and Chakravarti, A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol (2007) 25:26, 4127-4136. doi: 10.1200/JCO.2007.11.8554

6. Linz, U. Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466). Cancer (2010) 116:8, 1844-1846. doi: 10.1002/cncr.24950

7. Minniti, G., Amelio, D., Amichetti, M., Salvati, M., Muni, R., Bozzao, A., et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol (2010) 97:3, 377-381. doi: 10.1016/j.radonc.2010.08.020

8. Gupta, K., and Burns, T.C. Radiation-Induced Alterations in the Recurrent Glioblastoma Microenvironment: Therapeutic Implications. Front Oncol (2018) 8, 503. doi: 10.3389/fonc.2018.00503

9. Sarkaria, J.N., Hu, L.S., Parney, I.F., Pafundi, D.H., Brinkmann, D.H., Laack, N.N., et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol (2018) 20:2, 184-191. doi: 10.1093/neuonc/nox175

10. Bhowmik, A., Khan, R., and Ghosh, M.K. Blood brain barrier: a challenge for effectual therapy of brain tumors. Biomed Res Int (2015) 2015, 320941. doi: 10.1155/2015/320941

11. George, N., and Geller, H.M. Extracellular matrix and traumatic brain injury. J Neurosci Res (2018) 96:4, 573-588. doi: 10.1002/jnr.24151

12. Lee, W.H., Warrington, J.P., Sonntag, W.E., and Lee, Y.W. Irradiation alters MMP-2/TIMP-2 system and collagen type IV degradation in brain. Int J Radiat Oncol Biol Phys (2012) 82:5, 1559-1566. doi: 10.1016/j.ijrobp.2010.12.032

13. Azzam, E.I., Jay-Gerin, J.P., and Pain, D. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. Cancer Lett (2012) 327:1-2, 48-60. doi: 10.1016/j.canlet.2011.12.012

14. Kim, G.J., Chandrasekaran, K., and Morgan, W.F. Mitochondrial dysfunction, persistently elevated levels of reactive oxygen species and radiation-induced genomic instability: a review. Mutagenesis (2006) 21:6, 361-367. doi: 10.1093/mutage/gel048

15. Miura, Y. Oxidative stress, radiation-adaptive responses, and aging. J Radiat Res (2004) 45:3, 357-372. doi: 10.1269/jrr.45.357

16. Guntuku, L., Naidu, V.G., and Yerra, V.G. Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds. Curr Neuropharmacol (2016) 14:6, 567-583. doi: 10.2174/1570159x14666160121115641

17. Dar, S., Chhina, J., Mert, I., Chitale, D., Buekers, T., Kaur, H., et al. Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells. Sci Rep (2017) 7:1, 8760. doi: 10.1038/s41598-017-09206-0

18. Kato, Y., Maeda, T., Suzuki, A., and Baba, Y. Cancer metabolism: New insights into classic characteristics. Jpn Dent Sci Rev (2018) 54:1, 8-21. doi: 10.1016/j.jdsr.2017.08.003

19. Nam, S.O., Yotsumoto, F., Miyata, K., Fukagawa, S., Yamada, H., Kuroki, M., et al. Warburg effect regulated by amphiregulin in the development of colorectal cancer. Cancer Med (2015) 4:4, 575-587. doi: 10.1002/cam4.416

20. Wang, G., Wang, J.J., Yin, P.H., Xu, K., Wang, Y.Z., Shi, F., et al. New strategies for targeting glucose metabolism-mediated acidosis for colorectal cancer therapy. J Cell Physiol (2018) 234:1, 348-368. doi: 10.1002/jcp.26917

21. Strickland, M., and Stoll, E.A. Metabolic Reprogramming in Glioma. Front Cell Dev Biol (2017) 5, 43. doi: 10.3389/fcell.2017.00043

22. Kathagen-Buhmann, A., Schulte, A., Weller, J., Holz, M., Herold-Mende, C., Glass, R., et al. Glycolysis and the pentose phosphate pathway are differentially associated with the dichotomous regulation of glioblastoma cell migration versus proliferation. Neuro Oncol (2016) 18:9, 1219-1229. doi: 10.1093/neuonc/now024

23. Agnihotri, S., and Zadeh, G. Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions. Neuro Oncol (2016) 18:2, 160-172. doi: 10.1093/neuonc/nov125

24. Libby, C.J., Tran, A.N., Scott, S.E., Griguer, C., and Hjelmeland, A.B. The pro-tumorigenic effects of metabolic alterations in glioblastoma including brain tumor initiating cells. Biochim Biophys Acta Rev Cancer (2018) 1869:2, 175-188. doi: 10.1016/j.bbcan.2018.01.004

25. Yoshimura, M., Itasaka, S., Harada, H., and Hiraoka, M. Microenvironment and radiation therapy. Biomed Res Int (2013) 2013, 685308. doi: 10.1155/2013/685308

26. Betlazar, C., Middleton, R.J., Banati, R.B., and Liu, G.J. The impact of high and low dose ionising radiation on the central nervous system. Redox Biol (2016) 9, 144-156. doi: 10.1016/j.redox.2016.08.002

27. Arnold, K.M., Flynn, N.J., Raben, A., Romak, L., Yu, Y., Dicker, A.P., et al. The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules. Cancer Growth Metastasis (2018) 11, 1179064418761639. doi: 10.1177/1179064418761639

28. Yang, L., Yang, J., Li, G., Li, Y., Wu, R., Cheng, J., et al. Pathophysiological Responses in Rat and Mouse Models of Radiation-Induced Brain Injury. Mol Neurobiol (2017) 54:2, 1022-1032. doi: 10.1007/s12035-015-9628-x

29. Sundahl, N., Duprez, F., Ost, P., De Neve, W., and Mareel, M. Effects of radiation on the metastatic process. Mol Med (2018) 24:1, 16. doi: 10.1186/s10020-018-0015-8

30. Li, M.D., Burns, T.C., Kumar, S., Morgan, A.A., Sloan, S.A., and Palmer, T.D. Aging-like changes in the transcriptome of irradiated microglia. Glia (2015) 63:5, 754-767. doi: 10.1002/glia.22782

31.   Carlson, B.L., Pokorny, J.L., Schroeder, M.A., and Sarkaria, J.N. Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol (2011) Chapter 14, Unit 14 16. doi: 10.1002/0471141755.ph1416s52

32.   Schneider, C.A., Rasband, W.S., and Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods (2012) 9:7, 671-675. doi: 10.1038/nmeth.2089

33.   Schindelin, J., Rueden, C.T., Hiner, M.C., and Eliceiri, K.W. The ImageJ ecosystem: An open platform for biomedical image analysis. Mol Reprod Dev (2015) 82:7-8, 518-529. doi: 10.1002/mrd.22489

34.   Carpenter, A.E., Jones, T.R., Lamprecht, M.R., Clarke, C., Kang, I.H., Friman, O., et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol (2006) 7:10, R100. doi: 10.1186/gb-2006-7-10-r100

35.   Chen, J., Nam, H.W., Lee, M.R., Hinton, D.J., Choi, S., Kim, T., et al. Altered glutamatergic neurotransmission in the striatum regulates ethanol sensitivity and intake in mice lacking ENT1. Behav Brain Res (2010) 208:2, 636-642. doi: 10.1016/j.bbr.2010.01.011

36.   Govindaraju, V., Young, K., and Maudsley, A.A. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed (2000) 13:3, 129-153. doi: 10.1002/1099-1492(200005)13:3<129::aid-nbm619>3.0.co;2-v

37.   Nagana Gowda, G.A., Abell, L., Lee, C.F., Tian, R., and Raftery, D. Simultaneous Analysis of Major Coenzymes of Cellular Redox Reactions and Energy Using ex Vivo (1)H NMR Spectroscopy. Anal Chem (2016) 88:9, 4817-4824. doi: 10.1021/acs.analchem.6b00442

38.   Wishart, D.S., Feunang, Y.D., Marcu, A., Guo, A.C., Liang, K., Vazquez-Fresno, R., et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res (2018) 46:D1, D608-D617. doi: 10.1093/nar/gkx1089

39.   Wishart, D.S., Mandal, R., Stanislaus, A., and Ramirez-Gaona, M. Cancer Metabolomics and the Human Metabolome Database. Metabolites (2016) 6:1. doi: 10.3390/metabo6010010

40.   Robert, O., Sabatier, J., Desoubzdanne, D., Lalande, J., Balayssac, S., Gilard, V., et al. pH optimization for a reliable quantification of brain tumor cell and tissue extracts with (1)H NMR: focus on choline-containing compounds and taurine. Anal Bioanal Chem (2011) 399:2, 987-999. doi: 10.1007/s00216-010-4321-4

41.   Shao, W., Gu, J., Huang, C., Liu, D., Huang, H., Huang, Z., et al. Malignancy-associated metabolic profiling of human glioma cell lines using 1H NMR spectroscopy. Mol Cancer (2014) 13, 197. doi: 10.1186/1476-4598-13-197

42.   Sidorova-Darmos, E., Wither, R.G., Shulyakova, N., Fisher, C., Ratnam, M., Aarts, M., et al. Differential expression of sirtuin family members in the developing, adult, and aged rat brain. Front Aging Neurosci (2014) 6, 333. doi: 10.3389/fnagi.2014.00333

43.   Kind, T., Wohlgemuth, G., Lee, D.Y., Lu, Y., Palazoglu, M., Shahbaz, S., et al. FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Anal Chem (2009) 81:24, 10038-10048. doi: 10.1021/ac9019522

44.   Bland, J.M., and Altman, D.G. Survival probabilities (the Kaplan-Meier method). BMJ (1998) 317:7172, 1572. doi: 10.1136/bmj.317.7172.1572

45. Babicki, S., Arndt, D., Marcu, A., Liang, Y., Grant, J.R., Maciejewski, A., et al. Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res (2016) 44:W1, W147-153. doi: 10.1093/nar/gkw419

46. Dutta, T., Chai, H.S., Ward, L.E., Ghosh, A., Persson, X.M., Ford, G.C., et al. Concordance of changes in metabolic pathways based on plasma metabolomics and skeletal muscle transcriptomics in type 1 diabetes. Diabetes (2012) 61:5, 1004-1016. doi: 10.2337/db11-0874

47. Bellail, A.C., Hunter, S.B., Brat, D.J., Tan, C., and Van Meir, E.G. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol (2004) 36:6, 1046-1069. doi: 10.1016/j.biocel.2004.01.013

48. Sabatino, M.E., Grondona, E., Sosa, L.D.V., Mongi Bragato, B., Carreno, L., Juarez, V., et al. Oxidative stress and mitochondrial adaptive shift during pituitary tumoral growth. Free Radic Biol Med (2018) 120, 41-55. doi: 10.1016/j.freeradbiomed.2018.03.019

49. Fiaschi, T., and Chiarugi, P. Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison. Int J Cell Biol (2012) 2012, 762825. doi: 10.1155/2012/762825

50. Liao, Z., Chua, D., and Tan, N.S. Reactive oxygen species: a volatile driver of field cancerization and metastasis. Mol Cancer (2019) 18:1, 65. doi: 10.1186/s12943-019-0961-y

51. Puchades-Carrasco, L., and Pineda-Lucena, A. Metabolomics Applications in Precision Medicine: An Oncological Perspective. Curr Top Med Chem (2017) 17:24, 2740-2751. doi: 10.2174/1568026617666170707120034

52. Moren, L., Wibom, C., Bergstrom, P., Johansson, M., Antti, H., and Bergenheim, A.T. Characterization of the serum metabolome following radiation treatment in patients with high-grade gliomas. Radiat Oncol (2016) 11, 51. doi: 10.1186/s13014-016-0626-6

53. Wibom, C., Surowiec, I., Moren, L., Bergstrom, P., Johansson, M., Antti, H., et al. Metabolomic patterns in glioblastoma and changes during radiotherapy: a clinical microdialysis study. J Proteome Res (2010) 9:6, 2909-2919. doi: 10.1021/pr901088r

54. Moren, L., Bergenheim, A.T., Ghasimi, S., Brannstrom, T., Johansson, M., and Antti, H. Metabolomic Screening of Tumor Tissue and Serum in Glioma Patients Reveals Diagnostic and Prognostic Information. Metabolites (2015) 5:3, 502-520. doi: 10.3390/metabo5030502

55. Cuperlovic-Culf, M., Ferguson, D., Culf, A., Morin, P., Jr., and Touaibia, M. 1H NMR metabolomics analysis of glioblastoma subtypes: correlation between metabolomics and gene expression characteristics. J Biol Chem (2012) 287:24, 20164-20175. doi: 10.1074/jbc.M111.337196

56. Nakamizo, S., Sasayama, T., Shinohara, M., Irino, Y., Nishiumi, S., Nishihara, M., et al. GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients. J Neurooncol (2013) 113:1, 65-74. doi: 10.1007/s11060-013-1090-x

57. Sundgren, P.C., Nagesh, V., Elias, A., Tsien, C., Junck, L., Gomez Hassan, D.M., et al. Metabolic alterations: a biomarker for radiation-induced normal brain injury-an MR spectroscopy study. J Magn Reson Imaging (2009) 29:2, 291-297. doi: 10.1002/jmri.21657

58. Snezhkina, A.V., Kudryavtseva, A.V., Kardymon, O.L., Savvateeva, M.V., Melnikova, N.V., Krasnov, G.S., et al. ROS Generation and Antioxidant Defense Systems in Normal

and Malignant Cells. Oxid Med Cell Longev (2019) 2019**, 6175804. doi: 10.1155/2019/6175804

59. Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A.L., Pronzato, M.A., et al. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev (2013) 2013**, 972913. doi: 10.1155/2013/972913

60. Bauer, G. Targeting extracellular ROS signaling of tumor cells. Anticancer Res (2014) 34:4**, 1467-1482. doi:

61. Fitz, J.G. Regulation of cellular ATP release. Trans Am Clin Climatol Assoc (2007) 118**, 199-208. doi:

62. Pangrsic, T., Potokar, M., Stenovec, M., Kreft, M., Fabbretti, E., Nistri, A., et al. Exocytotic release of ATP from cultured astrocytes. J Biol Chem (2007) 282:39**, 28749-28758. doi: 10.1074/jbc.M700290200

63. Rathbone, M.P., Middlemiss, P.J., Gysbers, J.W., Andrew, C., Herman, M.A., Reed, J.K., et al. Trophic effects of purines in neurons and glial cells. Prog Neurobiol (1999) 59:6**, 663-690. doi: 10.1016/s0301-0082(99)00017-9

64. Wang, X., Li, Y., Qian, Y., Cao, Y., Shriwas, P., Zhang, H., et al. Extracellular ATP, as an energy and phosphorylating molecule, induces different types of drug resistances in cancer cells through ATP internalization and intracellular ATP level increase. Oncotarget (2017) 8:50**, 87860-87877. doi: 10.18632/oncotarget.21231

65. Kojima, S., Ohshima, Y., Nakatsukasa, H., and Tsukimoto, M. Role of ATP as a Key Signaling Molecule Mediating Radiation-Induced Biological Effects. Dose Response (2017) 15:1**, 1559325817690638. doi: 10.1177/1559325817690638

66. Zanotelli, M.R., Goldblatt, Z.E., Miller, J.P., Bordeleau, F., Li, J., Vanderburgh, J.A., et al. Regulation of ATP utilization during metastatic cell migration by collagen architecture. Mol Biol Cell (2018) 29:1**, 1-9. doi: 10.1091/mbc.E17-01-0041

67. Engl, E., and Attwell, D. Non-signalling energy use in the brain. J Physiol (2015) 593:16**, 3417-3429. doi: 10.1113/jphysiol.2014.282517

68. Han, T., Kang, D., Ji, D., Wang, X., Zhan, W., Fu, M., et al. How does cancer cell metabolism affect tumor migration and invasion? Cell Adh Migr (2013) 7:5**, 395-403. doi: 10.4161/cam.26345

69. Cao, Y., Wang, X., Li, Y., Evers, M., Zhang, H., and Chen, X. Extracellular and macropinocytosis internalized ATP work together to induce epithelial-mesenchymal transition and other early metastatic activities in lung cancer. Cancer Cell Int (2019) 19**, 254. doi: 10.1186/s12935-019-0973-0

70. Rathbone, M., Pilutti, L., Caciagli, F., and Jiang, S. Neurotrophic effects of extracellular guanosine. Nucleosides Nucleotides Nucleic Acids (2008) 27:6**, 666-672. doi: 10.1080/15257770802143913

71. Ciccarelli, R., Di Iorio, P., D'alimonte, I., Giuliani, P., Florio, T., Caciagli, F., et al. Cultured astrocyte proliferation induced by extracellular guanosine involves endogenous adenosine and is raised by the co-presence of microglia. Glia (2000) 29:3**, 202-211. doi:

72. Takai, Y., Sasaki, T., and Matozaki, T. Small GTP-binding proteins. Physiol Rev (2001) 81:1**, 153-208. doi: 10.1152/physrev.2001.81.1.153

73. Valerie, K., Yacoub, A., Hagan, M.P., Curiel, D.T., Fisher, P.B., Grant, S., et al. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther (2007) 6:3**, 789-801. doi: 10.1158/1535-7163.MCT-06-0596

74. Blanc, L., and Vidal, M. New insights into the function of Rab GTPases in the context of exosomal secretion. Small GTPases (2018) 9:1-2**,** 95-106. doi: 10.1080/21541248.2016.1264352

75. Lawson, C.D., and Ridley, A.J. Rho GTPase signaling complexes in cell migration and invasion. J Cell Biol (2018) 217:2**,** 447-457. doi: 10.1083/jcb.201612069

76. Rousseau, M., Gaugler, M.H., Rodallec, A., Bonnaud, S., Paris, F., and Corre, I. RhoA GTPase regulates radiation-induced alterations in endothelial cell adhesion and migration. Biochem Biophys Res Commun (2011) 414:4**,** 750-755. doi: 10.1016/j.bbrc.2011.09.150

77. Radhika, V., and Dhanasekaran, N. Transforming G proteins. Oncogene (2001) 20:13**,** 1607-1614. doi: 10.1038/sj.onc.1204274

78. Cormont, M., and Le Marchand-Brustel, Y. The role of small G-proteins in the regulation of glucose transport (review). Mol Membr Biol (2001) 18:3**,** 213-220. doi: 10.1080/09687680110077541

79. Sumita, K., Lo, Y.H., Takeuchi, K., Senda, M., Kofuji, S., Ikeda, Y., et al. The Lipid Kinase PI5P4Kbeta Is an Intracellular GTP Sensor for Metabolism and Tumorigenesis. Mol Cell (2016) 61:2**,** 187-198. doi: 10.1016/j.molcel.2015.12.011

80. Yuan, M., Liu, N., Wang, X., Tian, C., Ren, X., Zhang, H., et al. The Mechanism of Exosomes Function in Neurological Diseases: A Progressive Review. Curr Pharm Des (2018) 24:24**,** 2855-2861. doi: 10.2174/1381612824666180903113136

81. Osier, N., Motamedi, V., Edwards, K., Puccio, A., Diaz-Arrastia, R., Kenney, K., et al. Exosomes in Acquired Neurological Disorders: New Insights into Pathophysiology and Treatment. Mol Neurobiol (2018) 55:12**,** 9280-9293. doi: 10.1007/s12035-018-1054-4

82. Folmes, C.D., and Terzic, A. Energy metabolism in the acquisition and maintenance of stemness. Semin Cell Dev Biol (2016) 52**,** 68-75. doi: 10.1016/j.semcdb.2016.02.010

83. Mann, J., Ramakrishna, R., Magge, R., and Wernicke, A.G. Advances in Radiotherapy for Glioblastoma. Front Neurol (2017) 8**,** 748. doi: 10.3389/fneur.2017.00748

84. Brown, J.M., Carlson, D.J., and Brenner, D.J. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys (2014) 88:2**,** 254-262. doi: 10.1016/j.ijrobp.2013.07.022

85. Shibamoto, Y., Miyakawa, A., Otsuka, S., and Iwata, H. Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules? J Radiat Res (2016) 57 Suppl 1**,** i76-i82. doi: 10.1093/jrr/rrw015

86. Kaminaga, T., and Shirai, K. Radiation-induced brain metabolic changes in the acute and early delayed phase detected with quantitative proton magnetic resonance spectroscopy. J Comput Assist Tomogr (2005) 29:3**,** 293-297. doi: 10.1097/01.rct.0000161422.95625.8a

87. Moravan, M.J., Olschowka, J.A., Williams, J.P., and O'banion, M.K. Brain radiation injury leads to a dose- and time-dependent recruitment of peripheral myeloid cells that depends on CCR2 signaling. J Neuroinflammation (2016) 13**,** 30. doi: 10.1186/s12974-016-0496-8

88. Chen, H., Chong, Z.Z., De Toledo, S.M., Azzam, E.I., Elkabes, S., and Souayah, N. Delayed activation of human microglial cells by high dose ionizing radiation. Brain Res (2016) 1646**,** 193-198. doi: 10.1016/j.brainres.2016.06.002

89. Leroi, N., Lallemand, F., Coucke, P., Noel, A., and Martinive, P. Impacts of Ionizing Radiation on the Different Compartments of the Tumor Microenvironment. Front Pharmacol (2016) 7**,** 78. doi: 10.3389/fphar.2016.00078

90. Stapleton, S., Jaffray, D., and Milosevic, M. Radiation effects on the tumor microenvironment: Implications for nanomedicine delivery. Adv Drug Deliv Rev (2017) 109, 119-130. doi: 10.1016/j.addr.2016.05.021

91. Gonzalez, L.C., Ghadaouia, S., Martinez, A., and Rodier, F. Premature aging/senescence in cancer cells facing therapy: good or bad? Biogerontology (2016) 17:1, 71-87. doi: 10.1007/s10522-015-9593-9

92. Leonardi, G.C., Accardi, G., Monastero, R., Nicoletti, F., and Libra, M. Ageing: from inflammation to cancer. Immun Ageing (2018) 15, 1. doi: 10.1186/s12979-017-0112-5

93. Kaiser, L.G., Schuff, N., Cashdollar, N., and Weiner, M.W. Scyllo-inositol in normal aging human brain: 1H magnetic resonance spectroscopy study at 4 Tesla. NMR Biomed (2005) 18:1, 51-55. doi: 10.1002/nbm.927

94. Griffith, H.R., Den Hollander, J.A., Stewart, C.C., Evanochko, W.T., Buchthal, S.D., Harrell, L.E., et al. Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease. NMR Biomed (2007) 20:8, 709-716. doi: 10.1002/nbm.1132

95. James, E.L., Michalek, R.D., Pitiyage, G.N., De Castro, A.M., Vignola, K.S., Jones, J., et al. Senescent human fibroblasts show increased glycolysis and redox homeostasis with extracellular metabolomes that overlap with those of irreparable DNA damage, aging, and disease. J Proteome Res (2015) 14:4, 1854-1871. doi: 10.1021/pr501221g

96. Wyss, M., and Kaddurah-Daouk, R. Creatine and creatinine metabolism. Physiol Rev (2000) 80:3, 1107-1213. doi: 10.1152/physrev.2000.80.3.1107

97. Chan, K.C., Khong, P.L., Cheung, M.M., Wang, S., Cai, K.X., and Wu, E.X. MRI of late microstructural and metabolic alterations in radiation-induced brain injuries. J Magn Reson Imaging (2009) 29:5, 1013-1020. doi: 10.1002/jmri.21736

98. Zhang, Y., and Martin, S.G. Redox proteins and radiotherapy. Clin Oncol (R Coll Radiol) (2014) 26:5, 289-300. doi: 10.1016/j.clon.2014.02.003

99. Moss, R.W. Do antioxidants interfere with radiation therapy for cancer? Integr Cancer Ther (2007) 6:3, 281-292. doi: 10.1177/1534735407305655

100. Moss, R.W. Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants? Integr Cancer Ther (2006) 5:1, 63-82. doi: 10.1177/1534735405285882

101. Raviraj, J., Bokkasam, V.K., Kumar, V.S., Reddy, U.S., and Suman, V. Radiosensitizers, radioprotectors, and radiation mitigators. Indian J Dent Res (2014) 25:1, 83-90. doi: 10.4103/0970-9290.131142

102. Nair, C.K., Parida, D.K., and Nomura, T. Radioprotectors in radiotherapy. J Radiat Res (2001) 42:1, 21-37. doi: 10.1269/jrr.42.21

103. Simone, C.B., 2nd, Simone, N.L., Simone, V., and Simone, C.B. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med (2007) 13:1, 22-28. doi:

104. Simone, C.B., 2nd, Simone, N.L., Simone, V., and Simone, C.B. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, Part 2. Altern Ther Health Med (2007) 13:2, 40-47. doi:

105. Prasad, K.N. Multiple dietary antioxidants enhance the efficacy of standard and experimental cancer therapies and decrease their toxicity. Integr Cancer Ther (2004) 3:4, 310-322. doi: 10.1177/1534735404270936

106. Thyagarajan, A., and Sahu, R.P. Potential Contributions of Antioxidants to Cancer Therapy: Immunomodulation and Radiosensitization. Integr Cancer Ther (2018) 17:2, 210-216. doi: 10.1177/1534735416681639

107. Prasad, K.N., Cole, W.C., Kumar, B., and Che Prasad, K. Pros and cons of antioxidant use during radiation therapy. Cancer Treat Rev (2002) 28:2**,** 79-91. doi: 10.1053/ctrv.2002.0260

108. Prasanna, P.G., Narayanan, D., Hallett, K., Bernhard, E.J., Ahmed, M.M., Evans, G., et al. Radioprotectors and Radiomitigators for Improving Radiation Therapy: The Small Business Innovation Research (SBIR) Gateway for Accelerating Clinical Translation. Radiat Res (2015) 184:3**,** 235-248. doi: 10.1667/RR14186.1

109. Citrin, D., Cotrim, A.P., Hyodo, F., Baum, B.J., Krishna, M.C., and Mitchell, J.B. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist (2010) 15:4**,** 360-371. doi: 10.1634/theoncologist.2009-S104

110. Yoo, D., Jung, E., Noh, J., Hyun, H., Seon, S., Hong, S., et al. Glutathione-Depleting Pro-Oxidant as a Selective Anticancer Therapeutic Agent. ACS Omega (2019) 4:6**,** 10070-10077. doi: 10.1021/acsomega.9b00140

111. Du, J., Cullen, J.J., and Buettner, G.R. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta (2012) 1826:2**,** 443-457. doi: 10.1016/j.bbcan.2012.06.003

112. Baader, S.L., Bruchelt, G., Carmine, T.C., Lode, H.N., Rieth, A.G., and Niethammer, D. Ascorbic-acid-mediated iron release from cellular ferritin and its relation to the formation of DNA strand breaks in neuroblastoma cells. J Cancer Res Clin Oncol (1994) 120:7**,** 415-421. doi: 10.1007/bf01240141

113. Castro, M.L., Carson, G.M., Mcconnell, M.J., and Herst, P.M. High Dose Ascorbate Causes Both Genotoxic and Metabolic Stress in Glioma Cells. Antioxidants (Basel) (2017) 6:3. doi: 10.3390/antiox6030058

114. Grasso, C., Fabre, M.S., Collis, S.V., Castro, M.L., Field, C.S., Schleich, N., et al. Pharmacological doses of daily ascorbate protect tumors from radiation damage after a single dose of radiation in an intracranial mouse glioma model. Front Oncol (2014) 4**,** 356. doi: 10.3389/fonc.2014.00356

115. Schoenfeld, J.D., Sibenaller, Z.A., Mapuskar, K.A., Wagner, B.A., Cramer-Morales, K.L., Furqan, M., et al. O2(-) and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell (2017) 31:4**,** 487-500 e488. doi: 10.1016/j.ccell.2017.02.018

116. Chen, Q., Espey, M.G., Sun, A.Y., Pooput, C., Kirk, K.L., Krishna, M.C., et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A (2008) 105:32**,** 11105-11109. doi: 10.1073/pnas.0804226105

117. Sheweita, S.A., and Sheikh, B.Y. Can dietary antioxidants reduce the incidence of brain tumors? Curr Drug Metab (2011) 12:6**,** 587-593. doi: 10.2174/138920011795713733

Figure Legends:

Figure 1: A, Scheme of experiments. B, Representative IF images (at 4X, tiling) for hLamin A+C staining from 0Gy and 20Gy-IR mice coronal sections to assess tumor growth and invasion. C, Scheme illustrating steps involved in performing single cell count: mice brain coronal sections are stained for hLamin A+C –Cy3 (and Ki67 – Cy5), for both 0Gy and 20Gy. A defined region is selected and masked (area-squared in white). This masked area-image in single channels is imported into cell profiler software and cropped. This cropped image is used as the input image, pipeline for nuclei detection run, and single cell count obtained. Similar steps are performed for a defined region selected at centre of corpus callosum for hLaminA+C staining (images in box, on right). D, Top-panel: Representative images (at 20X) show IF staining at tumor; and the dot-plot of single cell count for hLamin A+C and Ki67 staining. Bottom-panel: Representative images (at 20X) show IF staining at center of corpus callosum, and dot-plot of single cell count for hLamin A+C. Statistical significance is represented as *p ≤ 0.05; **p ≤ 0.01.

Figure 2: Proton nuclear magnetic resonance (^{1}**H NMR**): A, (i) Principal component analysis, PCA between 0Gy and 20Gy. Supervised Orthogonal Projections to Latent Structures Discriminant Analysis, OPLS-DA shows further separation of 20Gy mice group from non-irradiated control based on differences in the metabolite composition of groups with predicted-VIP (variable importance in the projection) values shown in graph below. (ii) The graphs show, significantly altered metabolites between the 0Gy vs 20Gy. B, Multivariate analysis of NMR data performed using SIMCA 15 software for cohort of C57BL/6 mice, having groups as indicated. Supervised Partial Least Squares discriminant analysis (PLS-DA) performed shows, separation of all the four groups. Bar graphs show metabolites most significantly altered between groups. Statistical significance is represented as *q ≤ 0.05; **q ≤ 0.01.

Figure 3: Gas chromatography–mass spectrometry (GC-MS): A, (i) Heatmap for relative abundance of metabolites (i.e. normalized total peak area of metabolites for all mice within each group) between athymic nude mice groups, 0Gy and 20Gy. (ii) The graphs show significantly altered metabolites between 0Gy and 20Gy mice. B, (i) Heatmap for relative abundance of metabolites averaged for each group (i.e. normalized total peak area for metabolites, averaged for all mice within each group), between C57BL/6 mice grouped indicated. (ii) The graphs show significantly altered metabolites between 0Gy, 20Gy and 4Gyx10. C, General scheme for ascorbate (ASC) and glutathione (GSH) cycle in clearance of reactive oxygen species (ROS). Intermediates of ascorbic acid catabolism are represented in orange boxes. Reactions in green show ASC-dependent peroxide metabolism; reactions in the central grey box show GSH-dependent regeneration of ASC; and reactions in red show GSH-dependent peroxide metabolism. To the right: illustrates the expected metabolic alterations upon irradiation, which include increases in levels of ROS, utilization of GSH and ASC, with concomitant increase in by-products of ASC catabolism, threonic acid, and Oxalic acid. ASC; MDHA, monodehydroascorbate; MDHAR, monodehydroascorbate reductase; APX, ASC peroxidase; GR, GSH reductase; GRX, Glutaredoxin; PRX, Peroxiredoxin; ThrO, L-threonic acid; OxA, oxalic acid; DHA, Dehydroascorbic acid, GSH, GSH reduced; GSSG, GSH oxidized; NADP^{+}, nicotinamide adenine dinucleotide phosphate. Statistical significance is represented as *q ≤ 0.05; **q ≤ 0.01.

Figure 4: Immunostaining for microglia, with Iba-1: A, IF Images for microglial staining (Iba1/DAPI) and morphology (at 20X), in ipsilateral (IH) and contralateral (CH) hemispheres of

0Gy and 20Gy mice injected with GBM143 PDX line. B, the IF images skeletonized using Image J software to assess microglial morphology. C, the microglial staining in ipsilateral hemispheres of 0Gy-GBM143, and 20Gy-GBM143 compared with that of ipsilateral hemispheres of two separate mice cranially irradiated with 20Gy-single dose, however, not injected with any human-GBM PDX line. D, (i) Site of GBM143 injection at IH of mice having received ± cranial irradiation (ii) Stages of microglial activation observed in experimental setting.

Figure 5: Effects of radiation-associated metabolic alteration on GBM outcome: A, Survival curves: Graphs show difference between survival of irradiated mice cohorts injected with GBM143 24hrs post-irradiation (ST-IR) or 2 months post-irradiation (LT-IR). B, Proposed model for radiation associated metabolic alterations and their effects on cell processes and GBM outcome. The box marked with yellow outline (irradiated by RT) shows metabolic changes in the radiated brain stromal microenvironment, with rise in energy carriers ATP and GTP, and reduction in levels of antioxidants, ascorbate and glutathione, and the cellular processes affected by them. With IR, continued and excess rise in levels of energy carriers and expense of antioxidants within stromal cells of the brain can lead to altered extracellular milieu. Pathophysiological changes in the extracellular milieu, which can be immediate or long term caused by the radiation are enlisted in purple box. These alterations would collectively contribute to radiated stroma and GBM cell interactions that are permissive to GBM growth, aggressivity and recurrence.

Supplementary Figure 1: Tumor growth assessed post-moribund for cranially irradiated mice: A, Scheme for the slicing strategy: Mice brain was sectioned into four equidistant pieces (~1.8mm apart); Slices were made from each in the order of being 5μm thick coronal slices from the cerebral hemisphere only, Rostral to caudal for 22 slides, so as to cover a depth of 120μm from each of the 4 tissue pieces. These slices were arranged onto the glass slides, such that each slice on a slide is obtained from one of the respective 4 brain pieces, sectioned equidistantly. Two slides (1 and 22) were stained with H&E and evaluated for tumor growth. Tumor positive area was detected in slices obtained from two out of 4 sectioned pieces for most of the mice brain samples. Percent positive H and E staining was assessed for each. B, represents the arrangement of the slices on a glass slide, and evaluation of percent positive HE. C, Relative HE staining as observed for slices from 0Gy, 10Gy and 20Gy. Dot-plot for the overall tumor burden estimated in these groups.

Supplementary Figure 2: A, (i) Scheme for experiment involving ^{1}H-NMR and GC-MS. (ii) Multivariate analysis of ^{1}H-NMR data for C57BL/6 mice, having groups as indicated. B, Supervised Orthogonal Projections to Latent Structures Discriminant Analysis, OPLS-DA to show further separation of 0Gy, with irradiated group, IR (20Gy and 4Gyx10); (i) Total VIP (variable importance in the projection) values (ii) Predicted VIP (variable importance in the projection) values. Parameters involved in group separation using multivariate analysis in M1-M7 models are listed in the supplementary Table 1.

Supplementary Figure 3: Gas chromatography–mass spectrometry (GC-MS): The graphs show, relative abundance of metabolites between C57BL/6 mice groups. The significantly altered metabolites are categorized as per their molecular type or biological pathway involvement. Statistical significance is represented as $*q \leq 0.05$; $**q \leq 0.01$; $***q \leq 0.001$, $****q \leq 0.0001$.

Supplementary Table 1: Model parameters used for multivariate analysis of ^{1}H-NMR data.

(A) Scheme of experiments:

24Hrs → GBM143 IC injections → 30Days → Microdialysis (Contralateral Hemisphere) → Till Moribund ~58Days → Sac

0Gy 20Gy (10Gy)

→ Metabolomics (LC-MS)

→ Tissue collection Histology, IF

(B)
0Gy GBM143
20Gy GBM143

(C)

0Gy-GBM143 Tumor   20Gy-GBM143 Tumor

Center of corpus callosum
0Gy-GBM143   20Gy-G143

Crop   Crop

Image Crop in h-Lamin A+C

h-Lamin A+C

Ki67

Input image   Nuclei

Single Cell count

(D)

IF images: Tumor

0Gy GBM143

20Gy GBM143

Merged
h-Lamin A+C Ki67

Color channels split
h-Lamin A+C   Ki67

Cell proliferation at Tumor

hLamin A+C Cell count at Tumor   ns
0Gy   20Gy
N   5   6

Ki67 Cell count at Tumor   P=0.05
0Gy   20Gy
N   5   6

IF images: Center of corpus callosum

0Gy GBM143

20Gy GBM143

Merged
h-Lamin A+C Ki67

Color channels split
h-Lamin A+C   Ki67

Cell migration across center of Corpus callosum

hLamin A+C, Cell count Center of Corpus Callosum   *
0Gy   20Gy
N   5   7

(A)

Athymic Nude mice
0Gy vs 20Gy

(i)

M1: PCA   M2: OPLS-DA

(ii)

(B)

C57BL/6 mice
Groups: Aged, 0Gy, 20Gy, 4Gyx10

M3: PLS-DA

(A) Athymic Nude mice

(i)

(B) C57BL/6 mice

(i)

(ii)

(ii)

ASCORBIC ACID CATABOLISM

(C)

General scheme of Ascorbate and Glutathione cycle

Threonic acid + Oxalic acid

RT
ROS ↑
GSH ↓
ASC ↓
ThrO ↑
OxA ↑

(A) IF: Iba1/DAPI

IH   CH

0Gy-GBM143

20Gy-GBM143

**(B)** IF Image   IF image Skeletonized

0Gy-GBM143

20Gy-GBM143

(C) IF: Iba1/DAPI

| 0Gy-GBM143 | 20Gy-GBM143 | Radiation Control: 20Gy - Non-Injected |

IH   IH   IH: Mice 1   IH: Mice 2

(D)

(i)
- IR: 0Gy
+ IR: 20Gy

CH | IH

GBM143 injection

(ii)

0Gy-GBM143: CH
20Gy-GBM143: CH

Ramified   Hyper Ramified

0Gy GBM143: IH   20Gy GBM143: IH

Bushy   Ameboid

Resting Microglia

Activation ↑
Phagocytic activity ↑